@article{3139324,
    title = "Polymorphisms of genes coding for ghrelin and its receptor in relation
to anthropometry, circulating levels of IGF-I and IGFBP-3, and breast
cancer risk: a case-control study nested within the European Prospective
Investigation into Cancer and Nutrition (EPIC)",
    author = "Dossus, Laure and Mckay, James D. and Canzian, Federico and Wilkening, and Stefan and Rinaldi, Sabina and Biessy, Carine and Olsen, Anja and and Tjonneland, Anne and Jakobsen, Marianne U. and Overvad, Kim and and Clavel-Chapelon, Francoise and Boutron-Ruault, Marie-Christine and and Fournier, Agnes and Linseisen, Jakob and Lukanova, Annekatrin and and Boeing, Heiner and Fisher, Eva and Trichopoulou, Antonia and Georgila, and Christina and Trichopoulos, Dimitrios and Palli, Domenico and Krogh, and Vittorio and Tumino, Rosario and Vineis, Paolo and Quiros, Jose Ramon and and Sala, Nuria and Martinez-Garcia, Carmen and Dorronsoro, Miren and and Chirlaque, Maria-Dolores and Barricarte, Aurelio and van Duijnhoven, and Franzel J. B. and Bueno-de-Mesquita, H. B. and van Gils, Carla H. and and Peeters, Petra H. M. and Hallmans, Goran and Lenner, Per and Bingham, and Sheila and Khaw, Kay Tee and Key, Tim J. and Travis, Ruth C. and and Ferrari, Pietro and Jenab, Mazda and Riboli, Elio and Kaaks, Rudolf",
    journal = "Journal of Carcinogenesis",
    year = "2008",
    volume = "29",
    number = "7",
    pages = "1360-1366",
    publisher = "Oxford University Press",
    issn = "1477-3163",
    doi = "10.1093/carcin/bgn083",
    abstract = "Ghrelin, an endogenous ligand for the growth hormone secretagogue
receptor, has two major functions: the stimulation of the growth hormone
production and the stimulation of food intake. Accumulating evidence
also suggests a role of ghrelin in cancer development. We conducted a
case-control study on 1359 breast cancer cases and 2389 matched
controls, nested within the European Prospective Investigation into
Cancer and Nutrition, to examine the association of common genetic
variants in the genes coding for ghrelin (GHRL) and its receptor (GHSR)
with anthropometric measures, circulating insulin growth factor I
(IGF-I) and insulin-like growth factor-binding protein 3 and breast
cancer risk. Pair-wise tagging was used to select the 15 polymorphisms
that represent the majority of common genetic variants across the GHRL
and GHSR genes. A significant increase in breast cancer risk was
observed in carriers of the GHRL rs171407-G allele (odds ratio: 1.2;
95% confidence interval: 1.0-1.4; P = 0.02). The GHRL single-nucleotide
polymorphism rs375577 was associated with a 5% increase in IGF-I levels
(P = 0.01). A number of GHRL and GHSR polymorphisms were associated with
body mass index (BMI) and height (P between < 0.01 and 0.04). The
false-positive report probability (FPRP) approach suggests that these
results are noteworthy (FPRP < 0.20). The results presented here add to
a growing body of evidence that GHRL variations are associated with BMI.
Furthermore, we have observed evidence for association of GHRL
polymorphisms with circulating IGF-I levels and with breast cancer risk.
These associations, however, might also be due to chance findings and
further large studies are needed to confirm our results."
}